In a small study, the treatment was associated with a 4-fold increase in average ejaculation time.
Study shows it can provide durable oncologic control with a low risk of tumor recurrence.
Researchers observe benefit in prostate cancer patients with 2 or more adverse pathologic features.
Pelvic lymph node dissection in high-risk patients is 2.5 times more likely in those undergoing open rather than robotic-assisted surgery.
Men with non-palpable tumors had a 46% lower risk of positive surgical margins.
Parenteral testosterone undecanoate over 5 years found to decrease waist circumference and improve components of metabolic syndrome.
Alpha blockers and 5-alpha reductase inhibitors increase the risk of ejaculatory dysfunction, a systematic review and meta-analysis shows.
Risk is not eliminated if patients have risk factors for chronic kidney disease, such as hypertension and diabetes.
Patients are more than 9 times more likely to die from causes other than PCa, a new study shows.
It is associated with a 34.7% decrease in biochemical recurrence after radical prostatectomy versus patients with blood type A.
One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.
Modalities under investigation include laser ablation, hemiablative seed implantation, and results are promising.
For patients with metastatic disease receiving systemic treatment, a high BMI was found to improve overall survival.
Biochemical recurrence-free and metastasis-free survival can be achieved.
The trend is due mostly to an increasing incidence of visits by women.